“We’re never moving fast enough,” says Bob Segert, CEO of Athenahealth. Segert joins Bloomberg Intelligence analyst Jonathan Palmer to explain the strategic reset that reshaped Athenahealth: cutting losing bets, doubling down on ambulatory care and building around its cloud-native athenaOne platform to drive operating leverage. The conversation covers Athena’s aggressive AI pivot, its open-platform strategy and why speed, product discipline and better physician economics will determine the next market winners.

&ldquo;We&rsquo;re never moving fast enough,&rdquo; says Bob Segert, CEO of Athenahealth. Segert joins Bloomberg Intelligence analyst Jonathan Palmer to explain the strategic reset that reshaped Athenahealth: cutting losing bets, doubling down on ambulatory care and building around its cloud-native athenaOne platform to drive operating leverage. The conversation covers Athena&rsquo;s aggressive AI pivot, its open-platform strategy and why speed, product discipline and better physician economics will determine the next market winners.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/3569cad9-20c7-47d3-93f7-b42000c80d1e/transcript

“This deal [with Eli Lilly, announced on Sunday 29 March] is a combination of an asset licensing and collaboration. We’ve collaborated with Lilly in the past and they are actually one of the most active and expert users of our software,” says Alex Zhavoronkov, founder and co-CEO of Insilico Medicine. Zhavoronkov joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to explain how Insilico is using AI to compress drug-discovery timelines from years to months, pursue novel targets and compete with both big pharma and China’s fastest-moving biotech players. They also discuss the company’s rapid Lilly deal and why AI’s real edge may be before the clinic, not inside it.

&ldquo;This deal [with Eli Lilly, announced on Sunday 29 March] is a combination of an asset licensing and collaboration. We&rsquo;ve collaborated with Lilly in the past and they are actually one of the most active and expert users of our software,&rdquo; says Alex Zhavoronkov, founder and co-CEO of Insilico Medicine. Zhavoronkov joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to explain how Insilico is using AI to compress drug-discovery timelines from years to months, pursue novel targets and compete with both big pharma and China&rsquo;s fastest-moving biotech players. They also discuss the company&rsquo;s rapid Lilly deal and why AI&rsquo;s real edge may be before the clinic, not inside it.

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b01f802f-ccfb-4e98-81a7-b41e00a9ea9c/transcript

“I think 2026 is the year of fundamental, agentic transformation of the workflow.” Abridge co-founder and CTO Zack Lipton joins Bloomberg Intelligence analyst Jonathan Palmer to share how the company grew from a research-heavy idea into one of health care’s breakout AI leaders. Lipton breaks down the limits of point solutions, the complexity of evaluating generative AI in medicine, and why he sees the future not as a better digital scribe alone, but as a unified platform that can guide documentation, billing and care decisions in real time.

&ldquo;I think 2026 is the year of fundamental, agentic transformation of the workflow.&rdquo; Abridge co-founder and CTO Zack Lipton joins Bloomberg Intelligence analyst Jonathan Palmer to share how the company grew from a research-heavy idea into one of health care&rsquo;s breakout AI leaders. Lipton breaks down the limits of point solutions, the complexity of evaluating generative AI in medicine, and why he sees the future not as a better digital scribe alone, but as a unified platform that can guide documentation, billing and care decisions in real time.

Abridge Moving AI From Scribing to Clinical Workflows

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/96ac67ac-6c57-44dc-bf8d-b41701255070/transcript

“In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,” says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire’s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women’s health, the evolving AI landscape and the personal values — integrity, work ethic and mission — that shape how she invests and leads.

&ldquo;In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,&rdquo; says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire&rsquo;s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women&rsquo;s health, the evolving AI landscape and the personal values &mdash; integrity, work ethic and mission &mdash; that shape how she invests and leads.

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/11341ee2-b121-40cd-858d-b41200952d3e/transcript

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips